New Hope Clinical Research

NCT00216021

Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

NCT00216073

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

NCT00216138

Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

NCT00216216

Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

NCT00216164

Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00216151

Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma

NCT00234494

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

NCT00317200

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

NCT00367601

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00632541

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

NCT00613626

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT00730353

Sutent + Taxol for Advanced Esophageal Cancer

NCT00773474

Lonafarnib in Metastatic Breast Cancer

NCT00732303

Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer

NCT00859339

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

NCT01074970

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

NCT01071928

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

NCT01186458

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

NCT01215136

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

NCT01524991

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

NCT01681433

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

NCT01736917

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

NCT01732107

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

NCT01780545

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

NCT02101385

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

NCT02343952

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

NCT02375672

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

NCT02500121

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02499952

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

NCT02581059

Efficacy of Ginseng for Patients on Regorafenib

NCT02582749

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

NCT02581215

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

NCT02586610

Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer

NCT03041181

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

NCT03117309

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

NCT03035630

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

NCT02982720

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

NCT02549209

Pembro/Carbo/Taxol in Endometrial Cancer

NCT03241186

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

NCT03272217

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

NCT03396471

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

NCT03451331

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

NCT03547999

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

NCT03971409

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

NCT04848337

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

NCT05956041

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas